Kailash Jangid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kailash Jangid has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Vinod Kumar
Cranfield University
10 shared publications Bharti Devi
6 shared publicationsNaveen Kumar
Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Central University of Punjab, Bathinda, Punjab, 151401, India
6 shared publications- Vijay Kumar
Laboratory of Organic and Medicinal Chemistry, Department of Chemistry, Central University of Punjab, Bathinda, Punjab, 151401, India
5 shared publications Jasvinder Singh Bhatti
4 shared publications- Ashish Ranjan Dwivedi
Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, Punjab, 151401, India
3 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Identification of Dual Kinase Inhibitors Against CDK5 and GSK-3β Using a 3D-QSAR-Guided Virtual Screening Approach
A multi-target-directed ligand (MTDL) strategy has been proposed as an effective approach for treating complex multifactorial neurological disorders like Alzheimer's Disease. CDK5 and GSK-3β are key kinases involved in the hyperphosphorylation of tau protein, a hallmark of Alzheimer's disease pathology. Their dysregulation contributes to neurofibrillary tangles and neuronal dysfunction, making them promising therapeutic targets in AD treatment. Since, computer-aided drug design facilitates the identification of ligands with optimal binding affinity towards specific targets, here we have employed amalgamated ligand- and structure-based screening to identify potential dual inhibitors of CDK5 and GSK-3β. A Gaussian field-based 3D-QSAR pharmacophore model of purine derivatives against CDK5 was developed and validated, where the R2 and Q2 values were found to be statistically significant at 0.9505 and 0.9476, respectively. The best pharmacophore hypothesis model (ADDHRR_1) was used to screen the ChemDiv database followed by structure based virtual screening (with CDK5 and GSK-3β) which results in the identification of three hit molecules, i.e., ChemDiv-20539, ChemDiv-20547, and ChemDiv-20549. Out of these three hits, compound ChemDiv-20539 demonstrated superior docking scores of -10.436 kcal/mol with CDK5 and -9.486 kcal/mol with GSK-3β, and binding energies of -67.705 kcal/mol and -55.767 kcal/mol, respectively, compared to reference inhibitors dinaciclib (CDK5) and NP-12 (GSK-3β), which showed docking scores of -6.192 kcal/mol and -5.534 kcal/mol, and binding energies of -3.16 kcal/mol and -19.47 kcal/mol, respectively. MD simulation confirmed the stability of the compound-target complex, and high binding free energy values (ΔGMMPBSA = -24.69 kcal/mol for CDK5 and -28.15 kcal/mol for GSK-3β) than both standards, which further support the potential of ChemDiv-20539 as a promising drug candidate for AD therapy.
- 20 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessIdentification of Dual Kinase Inhibitors Against CDK5 and GSK-3β Using a 3D-QSAR-Guided Virtual Screening Approach
A multi-target-directed ligand (MTDL) strategy has been proposed as an effective approach for treating complex multifactorial neurological disorders like Alzheimer's Disease. CDK5 and GSK-3β are key kinases involved in the hyperphosphorylation of tau protein, a hallmark of Alzheimer's disease pathology. Their dysregulation contributes to neurofibrillary tangles and neuronal dysfunction, making them promising therapeutic targets in AD treatment. Since, computer-aided drug design facilitates the identification of ligands with optimal binding affinity towards specific targets, here we have employed amalgamated ligand- and structure-based screening to identify potential dual inhibitors of CDK5 and GSK-3β. A Gaussian field-based 3D-QSAR pharmacophore model of purine derivatives against CDK5 was developed and validated, where the R2 and Q2 values were found to be statistically significant at 0.9505 and 0.9476, respectively. The best pharmacophore hypothesis model (ADDHRR_1) was used to screen the ChemDiv database followed by structure based virtual screening (with CDK5 and GSK-3β) which results in the identification of three hit molecules, i.e., ChemDiv-20539, ChemDiv-20547, and ChemDiv-20549. Out of these three hits, compound ChemDiv-20539 demonstrated superior docking scores of -10.436 kcal/mol with CDK5 and -9.486 kcal/mol with GSK-3β, and binding energies of -67.705 kcal/mol and -55.767 kcal/mol, respectively, compared to reference inhibitors dinaciclib (CDK5) and NP-12 (GSK-3β), which showed docking scores of -6.192 kcal/mol and -5.534 kcal/mol, and binding energies of -3.16 kcal/mol and -19.47 kcal/mol, respectively. MD simulation confirmed the stability of the compound-target complex, and high binding free energy values (ΔGMMPBSA = -24.69 kcal/mol for CDK5 and -28.15 kcal/mol for GSK-3β) than both standards, which further support the potential of ChemDiv-20539 as a promising drug candidate for AD therapy.
- Open Access
- 9 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (15) , 13369-13380
Synthesis and biological evaluation of N / O -propargylated diarylpyrimidines as dual inhibitors of acetylcholinesterase and monoamine oxidase
Alzheimer's disease is a complex neurological disorder and is becoming a global health concern as the population ages. Considering the complex aetiology of the disease and ineptness of single-targeted drugs, the development of multi-targeted drugs emerges as the most effective strategy for the treatment of the disease. Cholinesterases and monoamine oxidases are amongst the most widely explored targets in Alzheimer’s disease, and their dual inhibition offers a promising approach for achieving multipotent therapeutic effects. Herein, we designed and synthesized a series of N/O-propargylated diaryl pyrimidines and evaluated their inhibitory activity against acetylcholinesterase (AChE) and monoamine oxidase (MAO) enzymes. Most of the compounds were found to be active against AChE, MAO-A and MAO-B. Amongst the synthesised derivatives of the series, compounds, compounds NV-1 and NV-9 exhibited a balanced multipotent activity profile against both the targets i.e. acetylcholinesterase and monoamine oxidase. Compounds NV-1 and NV-9 displayed IC50 values of 1.30 µM and 0.88 µM against AChE, 0.232 µM and 9.31 µM against MAO-A and 0.949 µM and 9.23 µM against MAO-B, respectively. In the reversibility inhibition studies, both the compounds were found to be reversible in nature. In kinetic inhibition studies, both NV-1 and NV-9 showed non-competitive inhibition for AChE. Additionally, NV-1 and NV-9 were found to be moderately neuroprotective in nature and exhibit no cytotoxicity at lower compound concentrations. In the partition coefficient studies (octanol/water), the compound NV-9 was found to be lipophilic in nature. Molecular docking studies illustrate their stability within the active cavity of both enzymes. Simulation studies confirmed the thermodynamic stability of these compounds within the cavity for up to 100 ns. Thus, the N/O-propargylated diarylpyrimidines have the potential to be developed as multipotent drugs for the treatment of Alzheimer's disease.
- 9 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 16 (15) , 13369-13380
Open AccessSynthesis and biological evaluation of N / O -propargylated diarylpyrimidines as dual inhibitors of acetylcholinesterase and monoamine oxidase
Alzheimer's disease is a complex neurological disorder and is becoming a global health concern as the population ages. Considering the complex aetiology of the disease and ineptness of single-targeted drugs, the development of multi-targeted drugs emerges as the most effective strategy for the treatment of the disease. Cholinesterases and monoamine oxidases are amongst the most widely explored targets in Alzheimer’s disease, and their dual inhibition offers a promising approach for achieving multipotent therapeutic effects. Herein, we designed and synthesized a series of N/O-propargylated diaryl pyrimidines and evaluated their inhibitory activity against acetylcholinesterase (AChE) and monoamine oxidase (MAO) enzymes. Most of the compounds were found to be active against AChE, MAO-A and MAO-B. Amongst the synthesised derivatives of the series, compounds, compounds NV-1 and NV-9 exhibited a balanced multipotent activity profile against both the targets i.e. acetylcholinesterase and monoamine oxidase. Compounds NV-1 and NV-9 displayed IC50 values of 1.30 µM and 0.88 µM against AChE, 0.232 µM and 9.31 µM against MAO-A and 0.949 µM and 9.23 µM against MAO-B, respectively. In the reversibility inhibition studies, both the compounds were found to be reversible in nature. In kinetic inhibition studies, both NV-1 and NV-9 showed non-competitive inhibition for AChE. Additionally, NV-1 and NV-9 were found to be moderately neuroprotective in nature and exhibit no cytotoxicity at lower compound concentrations. In the partition coefficient studies (octanol/water), the compound NV-9 was found to be lipophilic in nature. Molecular docking studies illustrate their stability within the active cavity of both enzymes. Simulation studies confirmed the thermodynamic stability of these compounds within the cavity for up to 100 ns. Thus, the N/O-propargylated diarylpyrimidines have the potential to be developed as multipotent drugs for the treatment of Alzheimer's disease.
- 3 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (24) , 4751-4768
Investigations of 3-Hydroxy Chromone Derivatives as Multipotent Therapeutics for the Treatment of Alzheimer’s Disease: In Silico and In Vitro Interventions and Fluorescence Studies
Chromone-based small organic molecules are designed and synthesized as putative multipotent ligands to intervene in several interlinked pathological pathways of Alzheimer's disease. The synthesized compounds were evaluated as acetylcholinesterase, monoamine oxidase, and amyloid β aggregation inhibitors using biochemical assays. Most of the compounds were found to inhibit the enzymes in a lower micromolar concentration range. In the series, two compounds, i.e., NSS-16 and NSS-18, displayed a balanced activity profile with the IC50 values of 1.77 and 1.53 μM against AChE and 2.06 and 1.51 μM against MAO-B. NSS-16 and NSS-18 showed moderate inhibitory activity against the self-induced Aβ aggregation with inhibition percentages of 17.8 and 24.0%, respectively. These compounds also showed potent antioxidant activity and formed metal chelates. In addition, the compounds were tested against SH-SY5Y neuronal cells and found to be neuroprotective and noncytotoxic. Moreover, the compounds inhibited reactive oxygen species (ROS) production up to 70% and exhibited a mixed type of inhibition in enzyme kinetic studies of AChE. These chromone derivatives showed a strong fluorescence intensity with a quantum yield of 30-50% and can be utilized in various biological studies including in vitro and in vivo assessments. Computational studies showed that the lead compounds fit well in the active cavity of enzymes and displayed thermodynamic stability for a time interval of 100 ns. Thus, these compounds displayed a multipotent activity profile and have the potential to be developed as potential therapeutics for AD.
- 3 December 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (24) , 4751-4768
Investigations of 3-Hydroxy Chromone Derivatives as Multipotent Therapeutics for the Treatment of Alzheimer’s Disease: In Silico and In Vitro Interventions and Fluorescence Studies
Chromone-based small organic molecules are designed and synthesized as putative multipotent ligands to intervene in several interlinked pathological pathways of Alzheimer's disease. The synthesized compounds were evaluated as acetylcholinesterase, monoamine oxidase, and amyloid β aggregation inhibitors using biochemical assays. Most of the compounds were found to inhibit the enzymes in a lower micromolar concentration range. In the series, two compounds, i.e., NSS-16 and NSS-18, displayed a balanced activity profile with the IC50 values of 1.77 and 1.53 μM against AChE and 2.06 and 1.51 μM against MAO-B. NSS-16 and NSS-18 showed moderate inhibitory activity against the self-induced Aβ aggregation with inhibition percentages of 17.8 and 24.0%, respectively. These compounds also showed potent antioxidant activity and formed metal chelates. In addition, the compounds were tested against SH-SY5Y neuronal cells and found to be neuroprotective and noncytotoxic. Moreover, the compounds inhibited reactive oxygen species (ROS) production up to 70% and exhibited a mixed type of inhibition in enzyme kinetic studies of AChE. These chromone derivatives showed a strong fluorescence intensity with a quantum yield of 30-50% and can be utilized in various biological studies including in vitro and in vivo assessments. Computational studies showed that the lead compounds fit well in the active cavity of enzymes and displayed thermodynamic stability for a time interval of 100 ns. Thus, these compounds displayed a multipotent activity profile and have the potential to be developed as potential therapeutics for AD.
- 17 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6153-6172
Investigation of the multifunctional profile of dihydroquinazoline derivatives as potential therapeutics for Alzheimer's disease
Multitarget directed ligands represent an innovative strategy in the management of Alzheimer's disease (AD) by addressing its multifactorial etiology.
- 17 September 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (12) , 6153-6172
Investigation of the multifunctional profile of dihydroquinazoline derivatives as potential therapeutics for Alzheimer's disease
Multitarget directed ligands represent an innovative strategy in the management of Alzheimer's disease (AD) by addressing its multifactorial etiology.
- 15 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110762
ML-based prediction to experimental validation: Development of dihydroquinazoline based multi-potent ligands as anti-Alzheimer's agents
- 15 July 2025
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 196 (Pt A) , 110762
ML-based prediction to experimental validation: Development of dihydroquinazoline based multi-potent ligands as anti-Alzheimer's agents
- 4 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 155, 108126
In vitro and in vivo Investigations of 4-Substituted 2-Phenylquinazoline derivatives as multipotent ligands for the treatment of Alzheimer’s disease
- 4 January 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 155, 108126
In vitro and in vivo Investigations of 4-Substituted 2-Phenylquinazoline derivatives as multipotent ligands for the treatment of Alzheimer’s disease
- 25 May 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (14) , 2565-2585
In Vitro and In Vivo Investigations of Chromone Derivatives as Potential Multitarget-Directed Ligands: Cognitive Amelioration Utilizing a Scopolamine-Induced Zebrafish Model
Alzheimer's disease is a complex neurological disorder linked with multiple pathological hallmarks. The interrelation of therapeutic targets assists in the enhancement of cognitive decline through interference with overall neuronal transmission. We have synthesized and screened various chromone derivatives as potential multitarget-directed ligands for the effective treatment of Alzheimer's disease. The synthesized compounds exhibited multipotent activity against AChE, BuChE, MAO-B, and amyloid β aggregation. Three potent compounds, i.e., VN-3, VN-14, and VN-19 were identified that displayed remarkable activities against different targets. These compounds displayed IC50 values of 80 nM, 2.52 μM, and 140 nM against the AChE enzyme, respectively, and IC50 values of 2.07 μM, 70 nM, and 450 nM against the MAO-B isoform, respectively. VN-3 displayed potent activity against self-induced Aβ1-42 aggregation with inhibition of 58.3%. In the ROS inhibition studies, the most potent compounds reduced the intracellular ROS levels up to 80% in SH-SY5Y cells at 25 μM concentration. The compounds were found to be neuroprotective and noncytotoxic even at a concentration of 25 μM against SH-SY5Y cells. In silico studies showed that the compounds were nicely accommodated in the active sites of the receptors along with thermodynamically stable orientations. Compound VN-19 exhibited a balanced multitargeting profile against AChE, BuChE, MAO-B, and Aβ1-42 enzymes and was further evaluated for in vivo activities on the scopolamine-induced zebrafish model. VN-19 was found to ameliorate the cognitive decline in zebrafish brains by protecting them against scopolamine-induced neurodegeneration. Thus, VN-3, VN-14, and VN-19 were identified as potent multitarget-directed ligands with a balanced activity profile against different targets and can be developed as therapeutics for AD.
- 25 May 2024
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 15 (14) , 2565-2585
In Vitro and In Vivo Investigations of Chromone Derivatives as Potential Multitarget-Directed Ligands: Cognitive Amelioration Utilizing a Scopolamine-Induced Zebrafish Model
Alzheimer's disease is a complex neurological disorder linked with multiple pathological hallmarks. The interrelation of therapeutic targets assists in the enhancement of cognitive decline through interference with overall neuronal transmission. We have synthesized and screened various chromone derivatives as potential multitarget-directed ligands for the effective treatment of Alzheimer's disease. The synthesized compounds exhibited multipotent activity against AChE, BuChE, MAO-B, and amyloid β aggregation. Three potent compounds, i.e., VN-3, VN-14, and VN-19 were identified that displayed remarkable activities against different targets. These compounds displayed IC50 values of 80 nM, 2.52 μM, and 140 nM against the AChE enzyme, respectively, and IC50 values of 2.07 μM, 70 nM, and 450 nM against the MAO-B isoform, respectively. VN-3 displayed potent activity against self-induced Aβ1-42 aggregation with inhibition of 58.3%. In the ROS inhibition studies, the most potent compounds reduced the intracellular ROS levels up to 80% in SH-SY5Y cells at 25 μM concentration. The compounds were found to be neuroprotective and noncytotoxic even at a concentration of 25 μM against SH-SY5Y cells. In silico studies showed that the compounds were nicely accommodated in the active sites of the receptors along with thermodynamically stable orientations. Compound VN-19 exhibited a balanced multitargeting profile against AChE, BuChE, MAO-B, and Aβ1-42 enzymes and was further evaluated for in vivo activities on the scopolamine-induced zebrafish model. VN-19 was found to ameliorate the cognitive decline in zebrafish brains by protecting them against scopolamine-induced neurodegeneration. Thus, VN-3, VN-14, and VN-19 were identified as potent multitarget-directed ligands with a balanced activity profile against different targets and can be developed as therapeutics for AD.